Please select the eligibility criteria that correspond to the clinical trial below.
Title: Lacunar-Brain Infarction Cerebral Hyperactivity And Atorvastatin Trial. A Placebo-Controlled Trial Of High-Dose Atorvastatin In Patients With Cerebral Small Vessel Disease.
Brief Summary: The main purpose of this study is to evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients.


Options:
A: Inclusion Criteria:

* clinically defined lacunar syndrome 3 months before inclusion
* small deep infarct on diffusion MRI (Diffusion Weighted Imaging)
* no atherothrombotic, cardio-embolic, or other rarer cause.

Exclusion Criteria:

* patients with past coronary event
* contra-indication for assessment of vasomotor reactivity
* patients being on statin therapy at the time of brain infarction
* contra-indication for statin therapy
* patient still under statin therapy
B: Inclusion Criteria:

* Holter monitoring at baseline which demonstrates a total of 15 minutes of ischemia and/or 3 ischemic events per 48 hours.
* Total cholesterol \> 5.2 mmol/L (200 mg/dL) on diet alone.

Exclusion Criteria:

* Myocardial infarction within 2 months prior to the study.
* Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol.
C: Inclusion Criteria:

• Diagnosed with Low High Density Lipoprotein Cholesterol (HDL-C) or hypercholesterolemia, after diet lead-in/washout of lipid therapies

Exclusion Criteria:

* History of coronary heart disease, or hardening of the arteries, or heart does not pump sufficiently well
* Hypertension or high blood pressure that is not under control or your study physician does not consider the electrical activity of heart (Electrocardiogram \[ECG\]) to be compatible with participation in the study
* History of a bad skin rash, a prior rash due to a drug or a history of chronic skin disorder (such as psoriasis or eczema)
* Intolerance to certain lipid modifying drugs (including statins and Cholesteryl Ester Transfer Protein (CETP) inhibitors)
* Not willing to stop taking prescription or over the counter drugs you use to control fats in your blood (like fish oil, niacin or statin) or pills to decrease your weight, including herbs
* Not willing to follow the diet (low-fat) that the study physician will recommend
* Have disease of liver, kidneys, muscles or other organs of body, a serious infection or cancer, or abnormal laboratory tests that study physician does not consider compatible with participation in the study
* Breastfeeding woman or a woman who can still become pregnant, but are not willing to use a valid birth control measure to prevent pregnancies
D: Inclusion Criteria:

* Healthy men age 60 to 75

Exclusion Criteria:

* History of significant cardiac, renal, pulmonary, hepatic, benign prostatic hyperplasia, or malignant disease, current alcohol or illicit drug abuse, or major psychiatric disorders.
* Current diagnoses of disorders known to affect bone metabolism including hyperthyroidism, hyperparathyroidism, osteomalacia, or Paget's disease.
* Current use of medications known to affect bone metabolism including estrogens, androgens, anti-estrogens, bisphosphonates, calcitonin, fluoride, oral or inhaled glucocorticoids, suppressive doses of thyroxine, lithium, pharmacological doses of vitamin D (greater than 2000 IU/day), or anti-convulsants.
* Cognitive or intellectual impairment that precludes complete understanding of the study protocol.
* History of deep vein thrombosis, pulmonary embolism, or clotting disorders.
* Serum 25-hydroxyvitamin D \< 15 ng/mL
* Serum parathyroid hormone (PTH) \< 10 or \> 65 pg/mL
* Serum thyroid stimulating hormone (TSH) \< 0.5 or \> 5.0 U/L
* Serum calcium \> 10.6 mg/dL
* Serum creatinine \> 2 mg/dL
* Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \> 2x the upper limit of normal
* Serum bilirubin \> 2 mg/dL
* Serum alkaline phosphatase \> 150 U/L
* Plasma hemoglobin \< 11 gm/dL
* Hematocrit \> 50
* Fracture within the last 6 months.
* Serum testosterone level \< 270 or \> 1070 ng/dL
* Serum prostate specific antigen (PSA) level \> 4 ug/L.
* International Prostate Symptom Score (IPSS) \> 19
* Systolic blood pressure \> 160 or diastolic blood pressure \> 95
* Framingham risk score greater than or equal to 20
* Difficulty walking 2 blocks

Answer: A